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Behcet’s disease (BD) is the only systemic vasculitis involving both arteries and vein in any sizes. It frequently encounters in
rheumatology clinics. It has some major morbidities and even fatal outcomes in some cases. The aim of this paper is to analyze the
main concepts on pathophysiology and treatment options in BD, focusing on cardiovascular aspects, thrombosis, and potential
future treatment.
1.Introduction
Behcet’s disease (BD) is a chronic, relapsing multisystem
autoinﬂammatory condition. It clinically diagnoses with
recurrent oral and/or genital aphthosis, mucocutaneous
lesions, central nervous system manifestation, and ocular,
vascular, articular, gastrointestinal, and inﬂammatory eye
lesions. Autoinﬂammatory conditions are a group of her-
itable inﬂammatory-mediated conditions characterized by
idiopathic attacks of systemic inﬂammation with lack of
known-speciﬁc antigens and antibodies or immune response
[1].Theseconditionsshareinsomeclinicalaspectsincluding
uveitis, fever, arthritis, and mucocutanous lesions as seen in
hyperimmunoglobulinemia D syndrome, periodic fever syn-
drome (HIDS), familial Mediterranean fever (FMF), and
tumor necrosis factor receptor-associated fever syndrome
(TRAPS).
Both genders at the third and fourth decade of life can
be aﬀected [2, 3]. Diﬀerent prevalences of BD are reported.
The highest prevalence was reported in Turkey (40–370 per
100000) [4], while this was 80 per 100000 in Iran [5]a n d
7 to 8.5 per 100000 in Japan. By contrast, the disease is less
commoninNorthAmerica,NorthernEurope,USA,UK,and
Germany (0.12 to 0.64) [6].
Vascular involvement has been reported in 7.7 to 38%
of BD cases, with mortality of about 20% in severe cases.
Despite lower sensitivity of this manifestation in BD, its
higher speciﬁcity with respect to eye and skin involvement
merits special consideration for Behcetologists. Venous
thrombosis could be as the initial presentation of BD [7].
Both veins and arteries with any size can be aﬀected. Most
authors believed that venous manifestation is more common
in BD. According to Hamza classiﬁcation there are ﬁve types
of vascular involvement in BD (Table 1). Early recognition of
vascular lesions is important because it seriously aﬀects BD
prognosis.Theleadingcauseofsuddendeathinpatientswith
BD is usually ruptured of a large aortic or arterial aneurysm
[8].
We performed a comprehensive search through MED-
LINE, Web of Science, Scopus, and Google Scholar for
recently published articles, using the following keywords:
Behcet’s disease, Behcet’s syndrome, cardiovascular, throm-
bosis, aneurysm, pseudoaneurysm, deep vein thrombosis,
embolism, heart, vessel, biological therapy, thrombophilia,
inﬂiximab, etanercept, rituximab, atherosclerosis, platelet,
and aspirin. Most of reviewed articles were from 2000–2011.
We emphasized on studies with higher evidence levels and
larger sample size cohorts.
The aim of this study is to review the main new concepts
on pathophysiology, clinical manifestation, and current and
potential future treatment in cardiovascular BD.2 ISRN Pharmacology
Table 1: Hamza classiﬁcation of vascular involvement in Behcet
disease.
Type Vascular involvement
I Venous thrombosis
II Arterial thrombosis
III Arterial aneurysm
IV Arterial thrombosis and aneurysm
V Venous thrombosis and arterial lesion
2.CardiovascularEtiopathogenesis
andPathology
T h er e a le t i o p a t h o g e n e s i so fB Di sn o tw e l lu n d e r s t o o d[ 9].
As in most autoinﬂammatory and autoimmune conditions,
genetic predisposition and environmental factors may play
some role in pathophysiology of BD. HLA-B51expression is
believed to be associated with more severe disease in several
studies and is related to familial BD [10]. In various studies
from Iran, Tunisia, Turkey, Israel, France, and Canada, it was
shown that (tumor necrosis factor) TNF-alpha-1031C allele
and polymorphism in IL-21, 10, and 8 genes are related to
pathogenesis of BD [11–17] .T h er o l eo fI L - 2 3 / I L - 1 7a x i si s
recently introduced in inducing BD [18, 19].
Delayed-type hypersensitivity to infections such as strep-
tococcus species (especially sanguis) are supposed in part by
some authors to be an important factor in inducing BD [20].
Thesebacterialantigensalongwithheatshockprotein(HSP)
60/65kDa activate T cells to promote inﬂammatory response
in BD [9, 21]. Besides from antiinﬂammatory activities of
antibiotics, favorable response of joint, and mucucutaneous
manifestationsofBDtobenzathinepenicillinmaypotentiate
the hypothesis of some role for infection [22–24].
Coagulation abnormalities and platelet overactivity may
have some additional role on endothelial damage, inﬂam-
mation and vascular pathologies in BD (Figure 1)[ 25–27].
Increased levels of nitric oxide (NO) after induction by
I n t e r f e r o n - g a m m aa r es e e ni na c t i v eB D[ 28]. In addition,
hypovitaminosis D was shown to be related to immune
aberrancy leading to BD [29].
It has been postulated that platelet-neutrophils com-
plexes (PNC) can play an important role in thrombosis-
inﬂammation which is seen in some critical vascular events
including BD[30–35].Alsoithasbeenshownthatinhibition
of PNC formation led to marked reduction in pulmonary
injuries and improved pulmonary function [33]. K¨ ohler et
al. found that PNC formation facilitates transendothelial
movement of platelets involving in process of thrombosis
inﬂammation in vitro and in vivo.
Elevation in some markers of endothelial dysfunction
(thrombomodulin and adhesion molecules) and low-grade
inﬂammation (proinﬂammatory cytokines, C-reactive pro-
tein, and serum amyloid A) disclose their important role in
pathophysiology of most immune-mediated cardiovascular
events in BD [36].
Impaired hypothalamus-pituitary-adrenal (HPA) axis
which is an important background in most autoimmune
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Figure 1: Correlation between hyperquagulopathy, endothelial
damage, thrombosis, aneurysm and abnormal ﬂow in pathophys-
iology of vascular Behcet diseas.
disease may be involved in etiopathogenesis of BD, while
this issue has been less addressed in the literatures. The
main reason for this is due to the fact that frequently
symptomsofpatientswillappearafteramajororevenminor
emotional stresses. This incompetent HPA axis may lead
to overexpression of proinﬂammatory cytokines deﬁnitely
involved in pathogenesis of BD.
The precise pathogenetic mechanism of prothrombotic
state in BD is unknown. It seems that thrombophilic factors
could contribute to thrombosis in BD. In addition, similar to
the other disorders with increased risk of thrombosis forma-
tion,thereisendothelialcellinjuryandhypercoagulablestate
in BD. Endothelial dysfunction due to antiendothelial cell
antibodies and elevated plasma Vascular Endothelial Growth
Factor (VEGF) levels lead to microcirculation disturbance
and increased blood viscosity and abnormal blood ﬂow [37–
39]. Furthermore, selectins, a group of adhesion molecules
consist of P and E-selectins that mediate leukocyte adhesion
to platelets and endothelium and have a role in thrombo-
genesis. E-selectin is expressed by activated endothelial cells
and P-selectin is synthesized and stored in platelets and
endothelial cells. Increased P and E-selectin level in BD was
reported in some studies [40–44].
In addition, it has been reported that factor V Leiden
[45–48] may be a factor in the development of thrombotic
events in BD. Also other factors which may play some
role in the hypercoagulability are protein C or protein S
deﬁciency [49, 50], impaired ﬁbrinolytic activity, increased
homocysteine levels [51, 52], decreased thrombomodulin
[53], elevated Lipoprotein (a) [54, 55], platelet hyperactivity,
high von Willebrand factor antigen, and the presence of
antiphospholipid antibodies [56–58]. Dyslipidaemia and
predominantly hypertriglyceridemia might also be risk fac-
tors. Besides inherent factors inducing thrombophilia in BD;
vasculitis and vessel wall inﬂammations are the other more
important factors. Vasculitis can lead to the enhancement ofISRN Pharmacology 3
platelet aggregation, and an impairment of ﬁbrinolysis re-
sulting in thrombosis [59].
Itiswellknownthatplateletisoneofthemostimportant
components in hemostasis. Following endothelial injury, the
ﬁrst step in thrombosis, formation is the platelet adherence,
aggregation and activation. Increased Mean Platelet Volume
(MPV), a marker of platelet function, is associated with
thrombosis in BD [60, 61]. Increased aggregation of platelet
in vitro in response to adenosine diphosphate (ADP) and
collagen is reported [62].
Cardiovascular pathology in BD represents a unique
spectrum of inﬂammation, thrombosis and aneurysm. It
seems that vasculitis is cornerstone of cardiovascular man-
ifestation in BD. Necrotizing leukocytoclastic or polymor-
phonuclear (PMN), obliterative perivasculitis and lympho-
plasma cell inﬁltration of capillaries, veins, and arteries,
and vasa vasorum (and not vasa nervorum) are the main
pathologic features in aﬀected tissues. Inﬁltration of PMNs
is a distinctive pathologic feature of BD addressing to thera-
peutic role of PMN inhibiting agents such as colchicines and
dapson. Vascular wall destruction due to inﬂammatory cell
inﬁltration leads to arterial wall weakening and aneurysmal
dilatation. In pseudoaneurysm all layers of intima, media,
a n da d v e n t i t i aa r en o ti n v o l v e da ss e e ni na n e u r y s m a ll e s i o n
(Figure 2). Although accelerated atherosclerosis is a major
contributor to cardiovascular events in most autoimmune
disorders like systemic lupus erythematous and rheumatoid
arthritis [63], several studies showed that atherosclerosis
is characteristically not increased in BD [64, 65]. Despite
nonincreased incidence of overt atherosclerosis in BD,
intima/media thickness (IMT) is shown to be increased in
some studies that may be due to nonatherosclerotic causes of
endothelial hyperactivity [66].
3. CardiacManifestations
Cardiac involvement is among the most life-threatening
complications in BD. They include pericarditis, coronary
artery stenosis or aneurysm, myocarditis, cardiomyopathy,
congestive heart failure, valvular pathology, endocarditis,
intracardiac thrombosis, and aneurysm of aorta or its
branches [67].
The incidence and nature of the cardiovascular involve-
ment in BD are not yet clearly documented [68]. Heart
involvement with frank clinical presentation is rare in BD
[67]. It was reported 1%–5% in a case series while it was
16.5% in a registry of Behc ¸et autopsy cases in Japan [69, 70].
Mortality of this complication is relatively high (around
20%). In addition cardiac involvement in BD can be seen
frequently without symptoms [71].
Pericarditis is the most common type of heart involve-
ment. Acute pericarditis, tamponade, constrictive pericardi-
tis, and even only pericardial eﬀusion without any symptom
have been reported [72–75].
Coronary artery disease (CAD) is rare in BD. It is more
commoninmaleyoungerthan40yearsold.Theincidenceof
coronary artery aneurysm is 1.5% to 5% [76]. CAD can lead
to clinical manifestation such as myocardial infarction, silent
ischemia, and stable or unstable angina. Aneurysm, stenosis,
occlusion, and arteritis are the most common etiologies for
CAD in BD [77]. Coronary aneurysms are more frequent
thanthestenosisandcanpresentasacutecoronarysyndrome
and myocardial infarction, but sometimes are symptomatic
[78]. Coronary occlusion is attributed to ﬁbrous intimal
thickening as a result of local vasculitis [79]. Conventional
coronary angiography is the procedure of choice for diagno-
sisofcoronaryarteryaneurysms.Twoformsofaneurysmcan
bedetectedbyangiography:saccularandfusiform.Ingeneral
population, acute myocardial infarction (AMI) is always
associated with atherosclerotic coronary artery disease. In
young adults with myocardial infarction, nonatherosclerotic
etiologies such as embolization, trauma, arteritis, spasm,
dissection, and congenital abnormalities should be consid-
ered. However, in BD, coronary arteritis has been supposed
as an independent pathophysiological mechanism for AMI.
Coronary arteritis may lead to myocardial infarction, but
in some of patients with MI, coronary artery is normal.
It seems that severe BD cases are to be more prone to
AMI. It was shown that occlusion is developed as a result
of thrombosis formation in CAD, consequently producing
AMI [80]. Understanding the etiology of AMI in BD may
be important for determination of best treatment strategy.
Silent myocardial infarction (SMI) has also been reported
in BD [81, 82]. The etiology of SMI is not clear, although
autonomic nervous dysfunction has been suggested as an
etiology. G¨ ull¨ u et al. [82]a n dT¨ urk¨ olmez et al. [81]r e p o r t e d
high prevalence of SMI on their studies (25% and 19.5%
among 36 and 41 patients, resp.). Myocardial perfusion
scintigraphy was recommended by T¨ urk¨ olmez et al. in
patients with long lasted BD for screening of SMI.
A few cases with intracardiac thrombus which often
preceding other manifestations of BD have been reported
[83]. These thrombi, found mainly in the right ventricle,
are often associated with pulmonary artery aneurysm [84].
The reason for predilection to involve right ventricular is
still unclear. However, both ventricular involvements have
also been reported [85]. Based on autopsy ﬁndings, it looks
that endomyocardial ﬁbrosis plays a role in the intracardiac
thrombus development in some patients [86] ,b u ti ti sn o t
clear whether they are secondary to underlying endocarditis
or endomyocardial ﬁbrosis, because in some case reports, a
normal underlying myocardium was described [87]. Due to
high speciﬁcity of right heart thrombus in BD, in any patient
with this ﬁnding, diagnosis of BD should be considered
[86, 88, 89]. Intracardiac thrombus is the major diﬀerential
diagnosis whenayoung patientpresents withanintracardiac
mass [90]. This makes enormous diagnosis of cardiac myx-
omainsomeinstances[91].Itisespeciallycommoninyoung
adultsBDpatientsinMiddleEast[68].Itisdiﬃculttospecify
the mechanism of intracardiac thrombi formation. Good
prognosis has been reported contrary to several recurrences
of thrombosis [68]. Intracardiac thrombus can lead to
superior vena cava syndrome [90, 92, 93] and pulmonary
embolism [83, 94–96].
Endocardial involvement may present with mitral and
aorticvalveprolapse,mitraloraorticinsuﬃciency,aneurysm
of sinus Valsalva, and endocarditis mimicking bacterial4 ISRN Pharmacology
Saccular
pseudoaneurysm
Adventitia
Media
Intima
(a)
Adventitia
Media
Intima
True aneurysm
(b)
Figure 2: Schematic demonstration of anatomy of pseudoaneurysm (a) and aneurysm (b) in Behcet disease. In true aneurysm all layers of
t h ev e s s e lw a l la r ei n v o l v e d .
endocarditis [67, 97, 98]. The Fibrosis secondary to endo-
cardial involvement in BD may predispose to intracardiac
thrombus formation [99]. It was reported that valvular
prolapse including mitral valve prolapse can be related to
vasculitisandtissuederangement[97].Mostoftheaneurysm
of the sinus Valsalva has been found in right coronary sinus
which project into the right atrium or ventricle. Usually
the problem is diagnosed after rupture of aneurysm. A
few cases of sinus Valsalva aneurysm in BD have been
reported. Usually they occurred in active phase of BD and
were enlarging progressively. Heart failure due to ruptured
aneurysm requires urgent surgical repair.
Conductive abnormalities were also reported in several
papers in the past [100, 101] that they could directly be
attributable or even nonrelated to BD per se.
4. Thrombosis
Thrombosis is one of the most common and important
features in BD with prevalence ranging 10–30% in diﬀerent
studies [102–107]. It was more common in males [102].
In most case series, fever is frequently found in vascular
thrombosis along with constitutional symptoms and high
acute phase response [108]. Deep vein thrombosis of the
lower extremities is the most frequent site for thrombosis
in BD (60–80% of vascular lesion) [103, 109]. Superﬁcial
thrombophlebitis is the next common lesion in BD which
may occur after venipuncture. This thrombosis has been
described at any sites such as cerebral sinuses, intracardiac,
renal, ulnar, subclavian, hepatic (Budd-Chiari syndrome) or
portal veins, and vena cava [110]. Budd-Chiari syndrome
and vena cava thrombosis are associated with increased
mortality. One of important clinical entities in vasculo-BD
is “venous claudication” due to iliac and/or femoral vein
thrombosis [111].
Classic vessel-related lesions in central nervous system
(CNS) are related to thrombosis, aneurysms, and frank vas-
culitis [112]. Both arteries (ischemic and embolic stroke-like
picture) and veins (dural sinus thrombosis) are vulnerable
in BD. Arterial embolism is also observed in BD secondary
to intracardiac thrombosis formation [113]. Most authors
believe that venous thrombosis in BD could not result in
embolism [114]. In addition, cerebral venous thrombosis
(CVT) is a serious manifestation of BD. It was reported
that CVT represents 7–30% of all CNS lesions of BD in
diﬀerent studies [115–119]. Frequently CVT is seen in a
young male patient approximately 5 years after initiation
of BD. However, CVT might be the presenting feature in
up to 20% of patients and could be subacute or chronic.
Persistent headache, papilledema, nausea, vomiting, and
focal deﬁcits are the main complaint among the patients.
In 60% of cases, superior sagittal sinus and transverse
sinus are the most common sites of CVT (Figure 3)[ 120].
The important complication of CVT is severe visual loss.
AssociationbetweenmajorvesseldisordersandCVThasalso
been described [121]. While parenchymal lesions in CNS are
categorized as a nonvascular lesions, but even parenchymal
lesions are resulted from some microvascular events [113].
5. Aneurysm
Arterial pathology in BD divided into two categories: occlu-
sive or aneurysmal lesion. Although it has been reported
thatvenousinvolvementisthemostcommonvasculo-Behcet
complication but Jamoussi reported that arterial involve-
ment is more frequently seen than the venous complication
[122]. The most severe complication is aneurysm formation
and rupture. Abdominal aorta is the common site of
aneurysmandapproximately60%ofreportedarteriallesions
associated with BD is aneurysms [123]. Aorta is among the
most common aﬀected arteries followed by the pulmonary
artery. In thoracoabdominal aorta, the abdominal aorta
shows more frequent aneurysm development than the tho-
racic aorta. Unusual aneurysms and pseudoaneurysms like
ulnar, celiac, subclavian, left anterior descending, tibioper-
oneal, iliac, and superior mesenteric artery aneurysm were
reported as rare manifestations of BD [124–129].
Pulmonary artery aneurysm (PAA) with an associated
rate of 1%–10% of patients in BD is the most common
pulmonary lesion [130]. Yekeler and Goueﬃcb e l i e v e d
that BD is the only vasculitis which could be associated
with PAA. PAA is usually occurred in main pulmonaryISRN Pharmacology 5
Figure 3:LateralviewofcerebralMRVduetothrombosisinBehcet
disease. Superior and inferior sagital and strait sinuses are not
visualized due to obliteration by thrombosis (courtesy of Dr. R.
Naﬁsi, radiologist).
arteries. Perihilar or parenchymal opacities can be seen on
chest radiographs; however, these radiographic features are
not speciﬁc and pathognomonic. Ruptured PAA and fatal
hemoptysis lead to poor prognosis.
Occurrence of PAA along with deep vein thrombosis is
deﬁned as Hughes-Stovin syndrome (HSS), which may be a
variant of BD. Less than 40 published cases of HSS have been
described. Infections and angiodysplasia are possible causes
in etiopathogenesis of HSS. The patients usuallypresent with
cough, dyspnea, fever, chest pain, and hemoptysis. Overall,
patientswithHSShaveapoor prognosis. Early diagnosis and
treatment may associate with better prognosis.
The occurrence of intracranial aneurysm in BD is very
rare (e.g., only one case in 316 and 119 patients was
reported in Benamour [131] and Al-Dalaan [106] studies,
resp.). Middle cerebral artery is the most common aﬀected
vessel and subarachnoid hemorrhage is the most presenting
manifestation secondary to aneurysm rupture. Association
of extracranial and intracranial aneurysm was reported in
several BD cases, also multiplicity almost always is seen
in vasculo-Behcet; thus more investigation in a patient
with extracranial aneurysm is recommended. The prognosis
of aneurysm has been diﬀered due to severity of the
hemorrhage and BD activity.
Theclinicalpresentationofaneurysmdependsondisease
stage and anatomic location of lesion. Most of the time,
aorticaneurysmsshowrapidprogressiontorupture,andasa
result, huge retroperitoneal hematoma or hemoperitoneum
is developed as initial manifestations. Aortic aneurysms are
often a pseudoaneurysm and usually originate from defects
located in the posterior or lateral walls of normally sized
aortaandthenextendintotheadjacentretroperitonealspace.
Angiographyisthebestmethodindiagnosisofaneurysm
and pseudoanurysm, but in BD the risk of new aneurysm
formation is high. Therefore noninvasive methods such as
digital subtraction angiography, contrast-enhanced tomog-
raphy and magnetic resonance angiography are the other
methods which have been used safely.
The pathogenesis of aneurysm in BD diﬀers from those
of atherosclerotic aneurysms. Vasculitis in BD leads to
destruction of the media, arterial dilatation and ﬁbrosis.
Inﬂammatory obliteration of the vasa vasorum and conse-
quent transmural necrosis may develop a pseudoanurysm or
rupture an arterial wall.
An important characteristic of aneurysm in BD is pre-
dilection for the recurrence, which can occur in diﬀerent
locations.
Matrix metalloproteinase proteins (MMP) which play
an important role in tissue remodeling and destruction
of extracellular matrix components are thought to have
signiﬁcant role in aneurysm formation. Pay et al. reported
that serum level of MMP-9 and MMP-2 are important
marker in vasculo-Behcet [132].
6. Treatment
6.1. General Considerations. Behcet’s disease is a condition
without known-speciﬁc etiology and evidence that supports
theimmunologicbasisit.Someevidenceaddressesinfectious
trigger forit. Therefore,cornerstoneof medical management
is manipulation of immune system and administering agents
against some putative microorganisms and ﬁnally surgical
intervention in case of vascular complications.
Managing vascular events in BD is debating [133]a n d
very important to all clinical disciplines including vascular
rheumatology, cardiovascular medicine, vascular surgery,
general internal medicine, general and interventional radiol-
ogy, and also thrombologists. Due to early diagnosis, aggres-
sive treatments and new techniques of vascular surgery, the
prognosis of large vessel involvement in BD is improving
[134].
Fewdoubleblindcontrolledtrialswerepresented,denot-
ing BD treatment. Most trials with new drugs are as case
reports or small case series. The newest EULAR recommen-
dations deal with emerging advances in management of BD.
Treatment plan is generally based on the symptom(s), the
organ involved, and severity of conditions that should be
tailored individually [135].
As mentioned earlier, BD is a multifeature condition.
In the next part, we emphasize on management of highly
morbid events or life threatening vascular BD.
6.2. Antiinﬂammatory and Cytotoxic Agents
6.2.1. Glucocorticoids (GCs). They are the pillar of manage-
ment in any organ involvement in autoinﬂammatory and
autoimmune disease; therefore corticosteroids are admin-
i s t e r e df o ry e a r si na l m o s ta n yo r g a ni n v o l v e m e n ti n
BD with dramatic response in most cases. Liberal use
of corticosteroids in 1950s led to severe and widespread
adverse reactions. So strategies to minimizing these side
eﬀects have been suggested then after. Administering the
“minimum eﬀective dose” (not traditional textbook based
doses) tailored for each individual patient could be rational
in handling with corticosteroids.
6.2.2. Azathioprine. One of the agents most studied in ran-
domized controlled trials [136] and nonrandomized trials in6 ISRN Pharmacology
BD is azathioprine [137–139] and almost all of them
reported good clinical response with negligible adverse
eﬀects. It does not mean that this agent is the utopian agent
in BD. Our anecdotal reports from Iran do not match with
this evidence. Despite EULAR recommendations conducted
by Hatemi et al. denoting use of azathioprine in neurologic
involvement in BD, we hardly use this agent in major
neurologic manifestations in our center (and also in Iran)
due to uncertainty or lack of clinical beneﬁt and cytopenia
in tolerable doses in our practice.
6.2.3. Cyclophosphamide. It is the ﬁrst line cytotoxic agent
in life threatening vascular events in BD. The EULAR
recommended this agent in both arterial (aneurysm) and
venous (thrombosis) involvement in central or peripheral
vascular bed. Its side eﬀects of leukopenia, hair loss, and
anorexia are reported to be nonsigniﬁcant.
6.2.4. Colchicine. The other most common systemic agent
used in BD iscolchicine. The mechanism of action for
colchicine is not fully understood, but it is shown that the
drug accumulates mostly in neutrophils and interferes with
microtubule assembly. Dosage adjustment in patients with
hepatic and or renal dysfunction is mandatory. Colchicine is
believed to not only prevent and treat oral and genital aphthi
and uveitis but also is used to prevent recurring intracardiac
thrombus in BD. Similarly it is used for some other autoin-
ﬂammatory conditions like FMF, pyoderma gangrenosum,
and other PMN-mediated conditions like Sweet’s syndrome
[140]. Therefore colchicine should be considered as a safe
systemic disease modifying antirheumatic drug (DMARD)
in any patient with potentially active BD. Alternatively,
considering inﬁltration of neutrophils in aﬀected vessel wall,
doxycycline, a matrix metaloproteinase inhibitor was used in
a 2 weeks period after surgery of abdominal aortic aneurysm
with better results than placebo [141].
6.2.5. Cyclosporine A. This agent with inhibition of IL-2 and
IL-17 is a powerful drug in controlling BD. Most studies
are focused on eye (uveitis rather retinal vasculitis) in BD.
Thalidomide, an old drug which discovered in 1950s, revis-
ited in recent years as a good antiinﬂammatory in conditions
like aphthous ulcerations, HIV-associated cachexia, inﬂam-
matory bowel diseases, and mucocutaneous and intestinal
BD with mechanism of inhibitions of angiogenesis and TNF-
alpha [142, 143].
6.3. Anticoagulation and Antiplatelet Agents. As all clini-
cians know, standard of care in deep vein thrombosis is
anticoagulation in almost all cases. Even there are some
indications to thrombolytic therapy in some selected cases
of DVTs. The challenging issue is holding anticoagulation
in setting of BD complicated with DVT due to lack of
risk of embolic events as supposed by Caspary [144]. We
emphasize that this notion is based on category IV evidence
of expert opinions. The authors of this review believe that
inﬂammation is an additional feature of BD complicated
with thrombosis. Presence of several thrombophilia states
in BD [25, 58, 145, 146]m a yo ﬀset in part the theory of
adhering clot to highly inﬂammatory veins with no risk of
embolisation. In our interdisciplinary discussion, we argued
about cases in whom repeated attacks of DVT may precede
months or years before full-picture BD and despite the
same story for pathophysiology of DVT in these cases, it
seems not to prudent withholding anticoagulation in these
cases. In addition, we believe any mentioned and well-
accepted risk of major bleeding in routine anticoagulation
therapies (about 7%) may be due to any underlying occult
vascular pathologies such as hidden aneurysms or vascular
disintegrities like subclinical BD. Saadoun et al. showed
that anticoagulation is not only an eﬀective but also a safe
treatment in cerebral venous thrombosis [115]. It seems that
thrombophiliainBDisasophisticatedprocessofintervening
inherent or hereditary condition, endothelial hyperactivity,
and low-grade inﬂammation [110]. Therefore, it is better to
just recommend management of DVT in BD to be accom-
plished by highly expert physicians and not to discourage
anticoagulation [147, 148] even in pediatric BD except for
pulmonary arterial involvement [149]. Some authors limit
control of inﬂammation for the purpose of prevention
of thrombosis rather than treatment of it and handling
complicated cases of cerebral sinus, vein and pulmonary
vein thrombosis is based on per-case decision made by a
multidisciplinary therapeutic team sometimes necessitating
more aggressive treatments such as local thrombolysis or
surgical interventions.
Regarding Intracardiac thrombus, some authors expe-
rienced successful thrombolytic therapy in the case of
recurrent right ventricular thrombosis [150, 151]. Khammar
and some other authors suggested colchicine, anticoagulant
therapy, and corticosteroids for intracardiac thrombosis in
BD [84, 152].
6.4. Neurovascular BD. In the case of neurovascular BD
treatment, (in contrary to eye, joint and mucocutaneous
studies with level Ib evidence) there is no high-quality
controlled trials and almost all studies are case-control or
comparative (level III) [114].
Benign vascular headache in BD is managed conserva-
tively as usual migraine [153]. In CVT, some authors use
anticoagulants along with short course glucocorticoids and
the others manage it as other parenchymal brain disease
in BD. In the newest recommendation, EULAR did not
address separately to CVT regarding anticoagulation usage
but recommended corticosteroids in dural sinus thrombosis.
It has also been emphasized that in CNS BD, cyclosporine A
should be withheld except in patients with concomitant eye
involvement. This is due to neurotoxicities of cyclosporine in
several reports. Vascular CNS aneurysms are managed as in
other locations.
6.5. Role of Surgery in Management of BD. Surgical repair is
the standard care in cases of organ threatening aneurysmal
dilatation, stenosis, or obstruction of clinically signiﬁcant
arteries. In some cases, ligation of aﬀected vessel (mostlyISRN Pharmacology 7
peripheral ones) is mandatory even in the cases of pul-
monary artery [154, 155]. Endovascular approach is a
minimally invasive technique for aneurysm repair and is
growingly advised by some authors [125, 134, 156]. In
BD, this technique has less complications and better results
comparing to atherosclerotic lesions [157]. Endarterectomy
was performed in rare incidence of bilateral common carotid
artery occlusion and chronic thromboembolic pulmonary
hypertension secondary to BD [158, 159]. Other approach
to some kinds of aneurysms is percutaneous emboliza-
tion of individual aneurysm using substances like n-butyl
cyanoacrylate [160]. The most frequently encountered post-
operative complication was anastomotic pseudoaneurysm
[125, 161]. Percutaneous transluminal stent angioplasty was
successfullyusedbyHanetal.inBDcomplicatedwithBudd-
Chiari syndrome [162]. This is important to mention that
systemic (and/or local) inﬂammation should be controlled
before any elective surgical intervention. Liu et al. used
medical therapy after vascular surgery with similar good
results [163]. Conventional immunosuppressive drugs are
frequently used as premedication to operative surgery [164].
6.6. Biologic Agents. Biologic agents are emerged in recent
decades and are targeted drugs against speciﬁc mediators
of inﬂammations. In general, biologic agents are the second
choice in cases of BD refractory to conventional immu-
nosuppression[165].Inonestudy,Bakietal.usedinﬂiximab
de novo without preceding glucocorticoids and cyclophos-
phamide in a man with PAA and reported complete remis-
sion in two years [166].
The most popular biologic agents are agents against
TNF-alpha (inﬂiximab, etanercept and adalimumab), B-
cell depleting agents (rituximab), and speciﬁc monoclonal
antibodies to interleukin (IL)-1 (anakinra), IL-6. Most of
studies on inﬂiximab deal with inﬂammatory eye disease
in BD. Considering the role of TNF-alpha in triggering
prothrombotic adhesion molecules, using TNF blocking
agents could be theoretically of some interest in vasculo-
BD. Inﬂiximab was used in two cases of PAA (with intrac-
ardiac thrombosis), one case with femoral profunda artery
aneurysm and two cases with magic syndrome with more
than a year of complete remission [166–168]. Employing
TNF (and probably other biological agents) in thrombosis
of BD was disappointing with especial regard to potential
prothrombotic activities and predisposition to frequent
autoantibody formation (notably anticardiolipin) of these
agents [169].
Inﬂiximab was used in several studies as an agent to
improve endothelia dysfunction and suppress low-grade
inﬂammation in the major cases of cardiovascular burden
in most autoimmune and autoinﬂammatory conditions [36,
170, 171].
Adalimumab is another TNF blocking agents which was
used in a 43 years old man with PAA. Neither etanercept nor
rituximab is reported to be useful in aneurysmal type BD
so far. In recent EULAR recommendations little information
is provided regarding these agents in cardiovascular BD. In
a recent systematic review the eﬀectiveness of targeted agents
are discussed in autoimmune posterior uveitis.
Our search results showed only two studies (both from
Iran) addressing the use of rituximab in retinal vasculitis in
BD and both had favorable response [172, 173] and several
trials mostly as case reports with etanercept uveoretinal
involvement even in juvenile BD [174, 175]. The reason for
the far less studies on biological agents in vascular BD could
be due to rather less frequent clinical vascular events and
limited time for multiple drug trials with newly lunched
drugs due to emergent nature of vasculo-Behcet.
Dyslipidemia, a known risk factor for cardiovascular
events in both autoimmune conditions and general popu-
lation, is accelerated with most biologic agents except for
adalimumab, rituximab, and etanercept [176].
Interferon alpha, a natural glycoproteins that has anti-
proliferative and antiviral properties, is used in retinal
vasculitis [177]. In a study it was shown that granulocyta-
pheresis is more beneﬁcial in 14 cases with long duration of
BD with uveoretinitis [178]. In addition, hematopoetic stem
celltransplantationwasusedinseveralcaseswithnecrotizing
vasculitis including three cases with BD with inconsistent
clinical results [179].
6.7. Future Direction in Managing Vascular BD. As optimum
management in BD is not achieved yet, future direction in
treating BD could be focused on better understanding of
common pathways in pathophysiology of vascular and
nonvascular BD. No doubt is about the future role of bio-
logic agents and targeted agents against proinﬂammatory
cytokines such as IL-15, 17, 21, and adhesion molecules in
controlling BD. Using biological agents targeting TNF-alpha
may improve endothelial dysfunction responsible for more
featuresofBD.Addressingmanydiseaseﬂare-upsaftermajor
orevenminorphysicaloremotionalstressors,weshouldalso
emphasize on potential therapeutic role of HPA axis support
to prevent and control BD. Taking into consideration the
important role of activated platelets and unique thrombosis-
inﬂammation relationship in BD, more clinical application
of antiplatelet (aspirin, clopidegrel) solely or in combination
with colchicine as a PMN inhibitor is justiﬁed [31]. Role of
statins as lipid lowering and antiinﬂammatory agents and
improving endothelial dysfunction in BD could be matter
of future studies for clinical use [180]. Detection of possible
putative triggering microorganism(s) could direct treatment
to some speciﬁc antibiotics and even categorize BD as a
potentially infectious disease.
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